For years, implants with the SLA® surface have delivered excellent results and high implant success rates.1 We followed this significant development in implant dentistry with the SLActive® surface, the next generation in surface technology. Designed to promote faster osseointegration and to provide higher predictability, SLActive® has become a central feature in the Straumann® Dental Implant System.
SLActive® is designed to deliver higher security and has shown more predictability in early treatment giving you confidence in the treatment outcome.
Most implant failures occur in the critical early period between week 2 and 4. SLActive® is designed to deliver higher security and has shown more predictability in early treatment, giving you confidence in the treatment outcome. Immediate and early loading with Straumann® SLActive implants yields excellent survival rates (98 % and 97 % after 1 year).*
SLActive® has been developed to optimize early implant stability and to reduce the risk during the critical early treatment. Animal test results show that SLActive® has 60 % more bone-to-implant contact*** compared to SLA® after 2 weeks**. For the challenges in daily practice, SLActive® offers higher treatment predictability and security for clinicians and patients.
* J. Ganeles et al. Immediate and early non-occlusal loading of Straumann® implants with SLActive® surface: 1 year results from a prospective multicenter randomized-controlled study. Clin. Oral Impl. Res. 2008;19:1119-1128.
** Raghavendra et al. Early wound healing around endosseous implants:a review of the literature. Int J Oral Maxillofac Implants. 2005 May-Jun;20(3):425-31.
*** D. Buser et al. Enhanced bone apposition to a chemically advanced SLA® titanium surface. 07/2004, JDR 83 (7): 529 – 533, 2004.
Although similar healing patterns were observed for both SLA® and SLActive® implants, bone-to-implant contact (BIC) was greater after 14 days and significantly greater after 28 days for SLActive®.
This substantially higher BIC-value results in improved treatment predictability and helps to minimize the potential for early implant failures.
Most implant failures occur in the critical early period between weeks 2 and 4.** SLActive® is designed to deliver higher security and has shown more predictability in early treatments, giving you confidence in the treatment outcome. Immediate and early loading with Straumann® SLActive® implants yields excellent survival rates of respectively 96.9 % and 96.7 % after 3 years.***
Bone crest stability in critical protocols. After 3-year follow-up visit no significant change in the proximal bone crest level of the SLActive® interface from implant placement.
* Lang, N. P., et al. Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants.Res 22.4 (2011): 349-56.
** Raghavendra, S., M. C. Wood, and T. D. Taylor. Early wound healing around endosseous implants: a review of the literature. Int.J Oral Maxillofac.Implants 20.3 (2005): 425-31.
*** Nicolau, P., et al. Immediate and Early Loading of Chemically Modified Implants in Posterior Jaws: 3-Year Results from a Prospective Randomized Multicenter Study. Clin.Implant.Dent.Relat Res. (2011).
All our Roxolid® implants are also equipped with the SLActive® surface, resulting in higher tensile strength combined with excellent osseointegration properties.
1 Bornstein MM, Wittneben JG, Brägger U, Buser D. Early loading at 21 days of non-submerged titanium implants with a chemically modified sandblasted and acid-etched surface: 3-year results of a prospective study in the posterior mandible. J. Periodontol. 2010 Jun;81(6):809–18.
2 Oates TW, Valderrama P, Bischof M, Nedir R, Jones A, Simpson J, Toutenburg H, Cochran DL. Enhanced implant stability with a chemically modified SLA® surface: a randomized pilot study. Int. J. Oral Maxillofac. Implants. 2007;22(5):755–760.
3 Schwarz F, Herten M, Sager M, Wieland M, Dard M,BeckerJ. Bone regeneration in dehiscence-type defects at chemically modified (SLActive) and conventional SLA titanium implants: A pilot study in dogs. J. Clin. Periodontol. 2007;34(1):78–86.
4 Schwarz F, Ferrari D, Herten M, Mihatovic I, Wieland M, Sager M, Becker J. Effects of surface hydrophilicity and microtopography on early stages of soft and hard tissue integration at non-submerged titanium implants: An immunohistochemical study in dogs. J. Periodontol. 2007;78(11):2171–2184.
5 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Histological and immunohistochemical analysis of initial and early subepithelial connective tissue attachment at chemicallymodified and conventional SLA® titanium implants. A pilot study in dogs. Clin. Oral Impl. Res. 2007;11(3):245–455.
6 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Histological and immunohistochemical analysis of initial and early osseous integration at chemically modified and conventional SLA® titanium implants: Preliminary results of a pilot study in dogs. Clin. Oral Impl. Res. 2007;11(4):481–488.
7 Buser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, Hoffmann B, Lussi A, Steinemann SG. Enhanced bone apposition to a chemically modified SLA titanium surface. J. Dent. Res. 2004 Jul;83(7):529–33.
8 Ganeles J, Zöllner A, Jackowski J, ten Bruggenkate C, Beagle J, Guerra F. Immediate and early loading of Straumann implants with a chemically modified surface (SLActive®) in the posterior mandible and maxilla: 1-year results from a prospective multicenter study. Clin. Oral Impl. Res. 2008;19:1119–1128.
9 Luongo G, Oteri G. A noninterventional study documenting use and success of implants with a new chemically modified titanium surface in daily dental practice. J. Oral Implantol. 2010;36(4):305–14.